BioMarin Pharmaceutical, Inc. (NASDAQ:BMRN)

CAPS Rating: 3 out of 5

The Company develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.

Recs

2
Player Avatar SkepBioInvestor (88.91) Submitted: 10/9/2012 4:08:55 PM : Outperform Start Price: $41.39 BMRN Score: +30.80

GALNS data coming up soon and the eternal buyout hype should keep it going up

Featured Broker Partners


Advertisement